A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 285 participants.
Also called NCT05769608
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 285 participants
- Sponsor
- Registry
-
NCT05769608
-
- Other papers using this trial's data
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05769608. Randomized; double masking; primary purpose treatment. Start 2023-03-13 (actual); primary completion 2025-01-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- Condition
- Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- lorundrostat Dose 1
- Intervention (Drug)
- lorundrostat Dose 2
- Lead sponsor
- Mineralys Therapeutics Inc.
Record details
- Record id
cardio:ct-nct05769608- Content hash
d2436d84e68d4e39b6419274327e5a318219f8069393569df3447ed4e927bcc2